[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563539":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"AdventHealth","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Open Label Main Arm","Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)",[12],"Drug: 18F-rhPSMA-7.3 (Posluma)",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","18F-rhPSMA-7.3 (Posluma)","PET Scan using Posluma for detection of early recurrence of prostate cancer.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"AdventHealth AdventHealth Oncology Research","CONTACT","407-303-2090","CFD.ResearchOncology@AdventHealth.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Orlando","Florida","32804","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-81.37924,28.53834,{"lat":38,"lon":37},[41,42],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":43,"role":23,"phone":19,"phoneExt":19,"email":19},"Guru Sonpavde, MD, MD",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[47],{"name":48,"class":49},"Blue Earth Diagnostics","INDUSTRY","100563539","phase-2-pet-scan-study-to-detect-prostate-cancer-in-patients-with-early-psa-recurrence-100563539",false,"NCT06617481","PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence","Inclusion Criteria:\n\n* History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.\n* An elevated PSA test result that is greater than or equal to 0.1 ng\u002Fml and less than 0.5\n\nExclusion Criteria:\n\n* Patients who are planned to have an x-ray contrast agent or other PET radiotracer \\& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.\n* Patients currently receiving Androgen Deprivation Therapy (ADT).","MALE","18 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.\n\nThe research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.",[67],"Prostate Cancer (Post Prostatectomy)",[69],"Rising PSA following cancer prostatectomy surgery","2024-10-22",{"date":72,"type":73},"2024-10-24","ACTUAL",{"date":75,"type":73},"2024-09-20",{"date":77,"type":61},"2027-10-10",{"name":5,"class":6},1]